Quest Diagnostics（DGX）株式概要
クエスト・ダイアグノスティックス・インコーポレイテッドは、米国で診断検査とサービスを提供している。 詳細
DGX Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Quest Diagnostics Incorporated 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$208.05 |
| 52週高値 | US$219.20 |
| 52週安値 | US$164.65 |
| ベータ | 0.57 |
| 1ヶ月の変化 | 1.72% |
| 3ヶ月変化 | 8.64% |
| 1年変化 | 21.35% |
| 3年間の変化 | 47.78% |
| 5年間の変化 | 55.18% |
| IPOからの変化 | 5,844.29% |
最新ニュース
分析記事 • Jun 21
Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative
Recent Share Performance and Business Scale Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat. Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures. See our latest analysis for Quest Diagnostics. At a share price of...
ナラティブの更新 • Jun 18
DGX: Advanced Diagnostics And AI Execution Will Support Safe Haven Appeal
Analysts have nudged their blended price targets on Quest Diagnostics higher, with a series of $5 to $20 upward revisions from multiple firms helping to justify only marginal tweaks to the model inputs and leaving the fair value estimate essentially unchanged at about $223.44 per share. Analyst Commentary Recent research on Quest Diagnostics clusters around a constructive stance, with several firms lifting price targets in increments of US$5 to US$20 while leaving underlying estimates and the blended fair value near US$223.44 per share.Recent updates
分析記事 • Jun 21
Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative
Recent Share Performance and Business Scale Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat. Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures. See our latest analysis for Quest Diagnostics. At a share price of...ナラティブの更新 • Jun 18
DGX: Advanced Diagnostics And AI Execution Will Support Safe Haven Appeal
Analysts have nudged their blended price targets on Quest Diagnostics higher, with a series of $5 to $20 upward revisions from multiple firms helping to justify only marginal tweaks to the model inputs and leaving the fair value estimate essentially unchanged at about $223.44 per share. Analyst Commentary Recent research on Quest Diagnostics clusters around a constructive stance, with several firms lifting price targets in increments of US$5 to US$20 while leaving underlying estimates and the blended fair value near US$223.44 per share.ナラティブの更新 • Jun 04
DGX: Raised 2026 Guidance And Execution Strength Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target nudged up by about $0.19 to roughly $223.44 as analysts fine-tuned assumptions around the discount rate, revenue growth, profit margins, and future P/E, following a series of recent target increases across major research firms. Analyst Commentary Recent research has converged around higher price targets for Quest Diagnostics, with several firms adjusting their models and one firm previously cutting its target while keeping a more tactical positive stance.ナラティブの更新 • May 13
DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.Seeking Alpha • May 07
Quest Diagnostics: Updating Levels After Q1 Earnings
Summary Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA. I maintain a 5/5 conviction rating, raising my Buy Threshold to $197 and holding the Sell Target at $227, reflecting confidence in DGX's long-term outlook. Read the full article on Seeking Alphaナラティブの更新 • Apr 20
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.ナラティブの更新 • Apr 05
DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.ナラティブの更新 • Mar 22
DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.ナラティブの更新 • Mar 07
DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.ナラティブの更新 • Feb 21
DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.ナラティブの更新 • Feb 06
DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.ナラティブの更新 • Jan 23
DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).ナラティブの更新 • Jan 06
DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.ナラティブの更新 • Dec 14
DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.ナラティブの更新 • Nov 29
DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.ナラティブの更新 • Nov 15
DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.ナラティブの更新 • Nov 01
DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.ナラティブの更新 • Oct 18
Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.分析記事 • Aug 20
Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics Incorporated's ( NYSE:DGX ) price-to-earnings (or "P/E") ratio of 21.6x might make it look like a...Seeking Alpha • Jan 28
Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Summary Quest Diagnostics' is reporting good numbers for the last 3 quarters, indicating the end of its dull period, which started post COVID. The street and management are expecting mid-single-digit topline growth and high-single-digit bottom-line growth. However, I have a rather moderate opinion on future top-line and bottom-line performance given the poor execution track record and higher leverage, limiting inorganic growth potential. Based on my fair value estimates, the company does not offer substantial upside from here. Read the full article on Seeking Alpha株主還元
| DGX | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -3.6% | 0.3% | 0.6% |
| 1Y | 21.3% | 31.7% | 19.5% |
業界別リターン: DGX過去 1 年間で31.7 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: DGX過去 1 年間で19.5 % の収益を上げたUS市場を上回りました。
価格変動
| DGX volatility | |
|---|---|
| DGX Average Weekly Movement | 3.4% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: DGX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: DGXの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1967 | 51,500 | Jim Davis | www.questdiagnostics.com |
クエスト・ダイアグノスティックス・インコーポレイテッドは、米国で診断検査とサービスを提供している。定期的、非定期的、高度な臨床検査、解剖学的病理検査、その他の診断情報サービスを開発、提供している。また、Quest Diagnosticsブランドのほか、AmeriPath、Dermpath Diagnostics、ExamOne、Quanumブランドのサービスを、検査室、患者サービスセンター、医院の瀉血担当者、コールセンター、移動瀉血担当者、看護師、その他の健康・福祉専門家のネットワークを通じて、医師、病院、患者・消費者、ヘルスプラン、政府機関、雇用主、小売業者、製薬会社・保険会社、商業臨床検査機関、アカウンタブル・ケア・オーガニゼーションに提供している。さらに、生命保険業界向けのリスク評価サービス、ヘルスケアITヘルスケアプロバイダーおよび支払者、病院検査室における検査およびメディカルディレクターサービス、心代謝および内分泌、がん、臨床薬物モニタリングおよび毒物学、自己免疫疾患を含む感染症、アルツハイマー病を含む神経学診断、および出生前遺伝学などの女性の健康、職場薬物検査、尿、毛髪、および口腔液検体サービス、および生体検査、インフルエンザ予防接種、および関連予防サービスを含む雇用者集団健康サービスを提供している。さらに、集団健康ソリューション、拡大ケアサービス、体外診断検査開発、検査室診断情報およびデジタルヘルス接続システム、データ収集、パラメディカル検査、臨床検査室検査および分析を含む引受サポートサービス、全国検体収集および健康データソリューションを提供している。クエスト・ダイアグノスティックスは1967年に設立され、ニュージャージー州セコーカスに本社を置いている。
Quest Diagnostics Incorporated 基礎のまとめ
| DGX 基礎統計学 | |
|---|---|
| 時価総額 | US$23.05b |
| 収益（TTM） | US$1.02b |
| 売上高(TTM) | US$11.28b |
22.6x
PER（株価収益率2.0x
P/SレシオDGX は割高か？
公正価値と評価分析を参照収益と収入
| DGX 損益計算書（TTM） | |
|---|---|
| 収益 | US$11.28b |
| 売上原価 | US$7.53b |
| 売上総利益 | US$3.75b |
| その他の費用 | US$2.73b |
| 収益 | US$1.02b |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 23, 2026
| 一株当たり利益（EPS） | 9.21 |
| グロス・マージン | 33.28% |
| 純利益率 | 9.04% |
| 有利子負債／自己資本比率 | 73.1% |
DGX の長期的なパフォーマンスは？
過去の実績と比較を見る| Quest Diagnostics 配当日 | |
|---|---|
| 配当落ち日 | Jul 08 2026 |
| 配当支払日 | Jul 22 2026 |
| 配当落ちまでの日数 | 2 days |
| 配当支払日までの日数 | 12 days |
DGX 配当は確実ですか？
DGX 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/09 05:29 |
| 終値 | 2026/07/09 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Quest Diagnostics Incorporated 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |